Diabetes

Some diabetes medications could help reduce alcohol consumption and alcohol-related health problems, particularly in those with obesity, results of a systematic review published in eClinicalMedicine suggested.

SAN DIEGO — Treatment with glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase among children with metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes.

PHILADELPHIA — In addition to COPD, patients frequently have other chronic diseases on top of their lung disease, including type 2 diabetes and osteoporosis, according to a presentation at the 2024 GOLD COPD International Conference.

SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated steatotic liver disease after liver transplantation, noted a presenter at The Liver Meeting.

A telemedicine-based nutrition counselling program emphasizing a low-carbohydrate diet resulted in sustained diabetes remission over half a decade for some individuals with type 2 diabetes, results of an open-label study showed.

The GLP-1 receptor agonist semaglutide may not only add another therapeutic option for chronic kidney disease, but it could also lead to changes in the way clinicians treat the condition.

CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data from a phase 2 study show.

CHICAGO — People living in historically redlined neighborhoods with poor access to healthy foods were more likely to have type 2 diabetes, hypertension, coronary heart disease and obesity, researchers reported.

CHICAGO — Among adults living in India with elevated BP, three different dual-medication polypills containing combinations of recommended first-line antihypertensive agents effectively lowered ambulatory BP, researchers reported.

CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.